Have you got a current driving licence? http://www.southsidejams.com/maillifepharmafzecom-690f.pdf ecolopharm.com  ChemoCentryx's shares were down 23 percent at $6.37 on theNasdaq on Tuesday. The losses added to a 30 percent declinesince late August, when GlaxoSmithKline Plc announcedthat a Crohn's disease drug it had licensed from ChemoCentryxhad failed a late-stage clinical trial. (Reporting by Shailesh Kuber; Editing by Sreejiraj Eluvangal)